Gastric Melanoma Metastaticum-a rare case
Session
Medicine and Nursing
Description
Malignant melanoma (MM) is the deadliest form of skin cancer and the most common carcinoma to metastasize into the gastrointestinal tract (GI). While the jejunum, ileum, colon, and rectum are common gastrointestinal sites of metastasis, met- astatic melanoma in the stomach is rare and usually not detected until late in the disease. We report a patient who presented with hematemesis, epigastric pain and weight loss. In the second esophagogastroduodenoscopy, after eight months from the first en- doscopic assessment a double ulcerative gastric mass was found and histopathology confirmed metastatic malignant melanoma. The complete surgical resection of GI metastatic MM in carefully selected patients not only provides symptom control, but has also been associated with an increase in overall survival, in the absence of another metastatic sites. Currently, the overall survival of patients with advanced metastatic MM who have been treated with a combination of immunotherapeutic agents reaches 52% at five years. The role of surgery for patients with the metastatic involvement of the GI tract with MM is evolving in in the era of effective systemic treatments.
Keywords:
metastatic malignant melanoma, gastrointestinal bleeding, histopathology
Proceedings Editor
Edmond Hajrizi
ISBN
978-9951-982-15-3
Location
UBT Kampus, Lipjan
Start Date
25-10-2024 9:00 AM
End Date
27-10-2024 6:00 PM
DOI
10.33107/ubt-ic.2024.383
Recommended Citation
Gashi, Zaim; Hamza, Astrit; Ukimeri, Blerina; Hamza, Valon; and Rakovica, Marigonë Zubaku, "Gastric Melanoma Metastaticum-a rare case" (2024). UBT International Conference. 38.
https://knowledgecenter.ubt-uni.net/conference/2024UBTIC/MN/38
Gastric Melanoma Metastaticum-a rare case
UBT Kampus, Lipjan
Malignant melanoma (MM) is the deadliest form of skin cancer and the most common carcinoma to metastasize into the gastrointestinal tract (GI). While the jejunum, ileum, colon, and rectum are common gastrointestinal sites of metastasis, met- astatic melanoma in the stomach is rare and usually not detected until late in the disease. We report a patient who presented with hematemesis, epigastric pain and weight loss. In the second esophagogastroduodenoscopy, after eight months from the first en- doscopic assessment a double ulcerative gastric mass was found and histopathology confirmed metastatic malignant melanoma. The complete surgical resection of GI metastatic MM in carefully selected patients not only provides symptom control, but has also been associated with an increase in overall survival, in the absence of another metastatic sites. Currently, the overall survival of patients with advanced metastatic MM who have been treated with a combination of immunotherapeutic agents reaches 52% at five years. The role of surgery for patients with the metastatic involvement of the GI tract with MM is evolving in in the era of effective systemic treatments.